Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00567710 | A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study | PHASE2 | COMPLETED | 360 | — | — | Jul 1, 2008 | Sep 1, 2009 | Jun 29, 2010 | 1 | United States |
| NCT00722176 | Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 | PHASE2 | COMPLETED | 220 | — | — | Jun 1, 2008 | Dec 1, 2009 | Jun 29, 2010 | 1 | United States |
| NCT00480571 | Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder | PHASE2 | COMPLETED | 90 | — | — | Jun 1, 2007 | Dec 1, 2007 | Jul 21, 2009 | 2 | Israel, Romania |
| Arm | Type | Description |
|---|---|---|
| I | EXPERIMENTAL | BL - 1020 lowdose |
| II | EXPERIMENTAL | BL 1020 high dose |
| III | PLACEBO_COMPARATOR | - |
| IV | ACTIVE_COMPARATOR | Risperidone |
| 1 | EXPERIMENTAL | BL-1020 10 mg |
| 2 | EXPERIMENTAL | BL-1020 10-30 mg |
| 3 | ACTIVE_COMPARATOR | risperidone |
| Name | Type | Description |
|---|---|---|
| BL - 1020 | DRUG | 10 mg/day |
| Placebo | DRUG | Capsules |
| Risperidone | DRUG | Capsules |
| BL-1020 | DRUG | 10 mg |
| BL-1020 10-30 mg | DRUG | BL-1020 10-30 mg |
| BL 1020 High Dose | DRUG | BL 1020 High Dose |
Inclusion Criteria: * Patient is male or female, 18-65 years of age, inclusive. * If female, the patient must be post-menopausal, or if fecund, must be abstinent or practicing an established method of birth control such as hormonal preparations (e.g., oral contraceptive tablets, hormonal implant de...